∗Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK

†Otopathology Laboratory, Massachusetts Eye and Ear

‡Department of Otolaryngology–Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts, USA

§ExpORL, Department of Neurosciences, Katholieke Universiteit Leuven, Leuven, Belgium

∥Eaton-Peabody Laboratories

¶Audiology Division, Massachusetts Eye and Ear, Boston, Massachusetts, USA

∗∗Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

Address correspondence and reprint requests to Alicia M. Quesnel, M.D., Otopathology Laboratory, Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114; E-mail: [email protected]

Sources of support and disclosure of funding: Royal College of Surgeons (England; C.S.), Anatomical Society (C.S.), Baroness de Turckheim fund (C.S.), Wellcome Trust Developing Concept Fund (RG93172/BANCE/40181; M.B.), the Biomedical Research Centre Cambridge (M.B.), NIH/NIDCD U24DC013983 (A.M.Q., M.Z.) and U24DC020849 (A.M.Q. and Foundation Flanders (1SD3322N;V414121N; A.G.).

A.M.Q.: Frequency Therapeutics (consulting, sponsored research agreement), Grace Medical (sponsored research, licensed patent), Alcon (consulting); M.B.: Decibel Therapeutics (consulting), Advanced Bionics (grant), Cochlear (grant), MEDEL (grant), Oticon Medical (grant); J.G.A.: Frequency Therapeutics (consulting). The remaining authors disclose no conflicts of interest.

Supplemental digital content is available in the text.